Polymorph of kras inhibitor, preparation method therefor, and use thereof
AssigneesGenfleet Therapeutics (Shanghai) Inc., Zhejiang Genfleet Therapeutics Co., Ltd.
InventorsFusheng ZHOU, Jinzhu ZHAO, Yudong CAO, Lun XIONG, Rongzhen SHI, Jiong LAN
Life of this patent
Estimating the term…
Abstract
Provided are a polymorph of a KRAS inhibitor, a preparation method therefor, and a use thereof. Specifically disclosed is a pharmaceutically acceptable salt of a compound 1 or a polymorph of the compound or pharmaceutically acceptable salt thereof, and further disclosed are a preparation method for the salt or polymorph and an application of the salt or polymorph in the treatment and/or prevention of KRAS G12C mutation-related diseases.
Claims20
A pharmaceutically acceptable salt of a compound, wherein the compound is compound 1 with a structure of
A polymorph, wherein the polymorph is a polymorph of a compound or a pharmaceutically acceptable salt of the compound;
- the compound is compound 1 with a structure of
Dependencies are inferred from the claim text.